Takeda Pharmaceutical (TAK) Capital Expenditures (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Capital Expenditures of -$337.6 million for Q2 2026, down 1.95% year-over-year from -$344.3 million in Q2 2025, and down 117.32% quarter-over-quarter from $1.9 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Capital Expenditures (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Capital Expenditures history runs 9 years deep, the most recent figure standing at -$337.6 million for Q2 2026.
- In Q2 2026, Capital Expenditures fell 1.95% year-over-year to -$337.6 million; the TTM figure through Jun 2026 stood at $1.1 billion (down 21.02% YoY), while the FY2026 annual figure was $1.2 billion, down 11.3% from the prior year.
- Capital Expenditures for Q2 2026 stood at -$337.6 million, down from $1.9 billion in the prior quarter.
- The five-year high for Capital Expenditures was $2.3 billion in Q1 2025, with the low at -$369.0 million in Q2 2024.
- The 5-year median for Capital Expenditures is -$271.3 million (2025), against an average of $338.9 million.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures rose 24.09% in 2022, then slumped 34.46% in 2023.
- Takeda Pharmaceutical's Capital Expenditures stood at -$236.9 million in 2022, then plunged by 34.46% to -$318.5 million in 2023, then rose by 6.88% to -$296.6 million in 2024, then grew by 8.78% to -$270.5 million in 2025, then fell by 24.8% to -$337.6 million in 2026.
- Business Quant data shows TAK's Capital Expenditures at -$337.6 million in Q2 2026, $1.9 billion in Q1 2026, and -$270.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -337.60 Mn |
| Jun 30, 2026 | -337.60 Mn |
| Mar 31, 2026 | 1.95 Bn |
| Mar 31, 2026 | 1.95 Bn |
| Dec 31, 2025 | -270.53 Mn |
| Dec 31, 2025 | -270.53 Mn |
| Sep 30, 2025 | -272.12 Mn |
| Sep 30, 2025 | -272.12 Mn |
| Jun 30, 2025 | -331.13 Mn |
| Jun 30, 2025 | -331.13 Mn |
| Mar 31, 2025 | 2.31 Bn |
| Mar 31, 2025 | 2.31 Bn |
| Dec 31, 2024 | -296.58 Mn |
| Dec 31, 2024 | -296.58 Mn |
| Sep 30, 2024 | -331.67 Mn |
| Sep 30, 2024 | -331.67 Mn |
| Jun 30, 2024 | -369.00 Mn |
| Jun 30, 2024 | -369.00 Mn |
| Mar 31, 2024 | 2.07 Bn |
| Mar 31, 2024 | 2.07 Bn |